Sunday, September 26, 2021

Biocon Biologics' insulin manufacturing facility in Malaysia completes USFDA (PAI) Inspection

At the conclusion of the inspection, the agency has issued a Form 483 with a total of 6 observations.

from India Infoline News Service https://ift.tt/2XOeVVB
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)